JPOST Repositoryapplication/xmlhttps://storage.jpostdb.org/JPST001356/files/210115masuta_again.xlsxhttps://storage.jpostdb.org/JPST001356/files/210115masuta_etp3.rawhttps://storage.jpostdb.org/JPST001356/files/210115masuta_young3.rawhttps://storage.jpostdb.org/JPST001356/files/210115masuta_young2.rawhttps://storage.jpostdb.org/JPST001356/files/210115masuta_young1.rawhttps://storage.jpostdb.org/JPST001356/files/210115masuta_etp1.rawhttps://storage.jpostdb.org/JPST001356/files/210115masuta_etp2.rawhttps://storage.jpostdb.org/JPST001356/files/210115masuta_again.pdResultprimaryOK200ProteomicsShigeo MurataHomo Sapiens (human)https://repository.jpostdb.org/entry/JPST001356University of TokyojPOSTETP, Rev, p27K, PROS27, ethionamidum, etionamida, Sez4, REVOLUTA, Etioniamid, Ethyonomide, MUP24_16, Ethioniamide, Ethinamide, LFQ, Ethylisothiamide, preT.ETP.Th, IFL., IFL1, MUP24.16, HOMEODOMAIN-LEUCINE ZIPPER PROTEIN IFL1, 2-ethyl-4-thiopyridylamide, HOMEODOMAIN-LEUCINE ZIPPER PROTEIN, Etionamid, IOTA, Trecator, INTERFASCICULAR FIBERLESS, Rev3, ETH, Etionamide, INTERFASCICULAR FIBERLESS 1Raw, ion, Lysine Hydrochloride, MUP24_16, Ethylisothiamide, prevention, Long Term, nodus primitivus., MUP24.16, 5730420M11Rik, dmTAF[[II]]230, Polypeptides, Lysine Acetate, Biotin, dorsal marginal zone, Method, Etionamid, B1, 2, 2-amino-3-mercaptopropanoic acid, Rev3, WMS, L Lysine, SET, C, Divorced, C79325, TFIID TAF250, ethionamidum, cel, K, M, cis-Hexahydro-2-oxo-1H-thieno(3, Divorces, T6G21.3, AI047805, DmelCG4299, HOMEODOMAIN-LEUCINE ZIPPER PROTEIN IFL1, isolation and purification, Biotinylations, set, LYS, column, ACN, Lysin, D1, Acn, Half Cystine, SGS, LC-MS2, Rev, dTAF[[II]]230, preventive therapy, Stars, Bonin Islands, Rombellin, Zinc Cysteinate, REVOLUTA, acetylation, TAF200, Longterm Effect, Ethinamide, Procedure, (3aS-(3aalpha, ACMICD, Dm1, Methionin, Hmet, (2R)-2-amino-3-sulfanylpropanoic acid, 1H-Thieno(3, HLA-DR-associated protein II, DI-2, Sez4, I-2Dm, Methodological, alpha, beta Trypsin, human, I-2PP1, TAF-IBETA, Taf250, liquid chromatography-tandem mass spectroscopy, DMZ, TAF-Ibeta, STARS, D-(+)-biotin, Liquimeth, Biokur, TAF230, Deacura, 2-amino-4-(methylsulfanyl)butanoic acid, Effects, Biocatalysts, Medebiotin, L-Zystein, preT.ETP.Th, precursor, thomson, protein-containing complex, 17alpha)-isomer, CG7826, mass-to-charge ratio, Human, isolation, LC-MSMS, CG7835, Gene Products, CG42273, Lysine, Half-Cystine, Gelfert, Technique, Man, Biotin Hermes, dTAF[[II]]250, Acinus, Longterm, cell, nodus primitivus, L Cysteine, E-920, beta-Trypsin, 2pp2a, Hcys, Long-Term, ions, man, CG10574, acinusL, Study, Injectable, dTAF250, 4-d]imidazole-4-valeric acid, Enzyme, 2PP2A, 2-amino-4-(methylthio)butanoic acid, acinusS, CYSTEINE, dSET, dSet, Trecator, FREE CYSTEINE, peptidos, INTERFASCICULAR FIBERLESS, (2R)-2-amino-3-mercaptopropanoic acid, ETH, metionina, PTHB1, ETP, Proteins, Roche, BG:DS00004.13, backward, L-Isomer, Cell, mKIAA0670, Engine, dTAF230, native protein, I-2PP2A, C18, Acetate, chemical analysis, Long Term Effects, Dm I-2, TAF[[II]]250/230, 5alpha, MFS1, L-Lysine, Met, Taf[[II]]250, AU020952, Col4a-1, Gabunat, ensemble, etionamida, prophylaxis, Separations, Striated muscle activator of Rho-dependent signaling, (R)-2-amino-3-mercaptopropanoic acid, 4)imidazole-4-valeric acid, 2-Amino-3-mercaptopropionic acid, Longterm Effects, ME-IV, plan specification, Gene Proteins, HOMEODOMAIN-LEUCINE ZIPPER PROTEIN, control, liquid chromatography tandem mass spectrometry, E920, Enisyl, reversed, liquid chromatography tandem mass spectroscopy, IPP2A2, Bru, E 920, vitamin B7, determination, LFQ, protein, Techniques, L-Isomer Methionine, Methionine, peptido, BANF, 6aR)-Hexahydro-2-oxo-1H-thieno[3, Min, Cystein, protein aggregate, prevention and control, Injectables, Effect, DmelCG42273, Svc, 3-hydroxy-5-estrane-17-carbonitrile, LCMSMS, Man (Taxonomy), reference sample, peptides, TAF-I, cisteina, (3aS, 2610036I19Rik, 2610510L13Rik, biotina, min, epsilon-diaminocaproic acid, Ethioniamide, mAPC, biotine, purification, preventive measures, IGAAD, fSAP152, Hermes, Methodological Studies, DmelCG10574, ppm, biotinum, GPHYSD2, Racemethionine, Long-Term Effects, phapii, Medobiotin, Modern, LC-MS/MS, 2-Amino-4-(methylthio)butyric acid, Dmel_CG7826, Ethyonomide, StF-IT-1, Th, Search, TAFII-250, TAF250/230, Cys, 4S, 4-d)imidazole-4-pentanoic acid, TAFII250, Ionen, lysine, Biotin Ratiopharm, Henson's node, 4-d)imidazoline-4-valeric acid, Dmel_CG7835, D-Biotin, Mnb, MNB, parent ion, Biotine Roche, MS/MS, IFL, L-Cysteine, MASS, CG4299, AW124434, CG17603, TAF[[II]], Methodological Study, L-Cystein, nanospray, precursor ion, SR3-5, Biocatalyst, cis-(+)-Tetrahydro-2-oxothieno[3, Polypeptide, Etionamide, i2pp2a, 4-d]imidazol-4-yl)pentanoic acid, d230, human being, Cysteine Hydrochloride, Procedures, Biotine, L Isomer, FBN, Gene, dTAFII250, Vitamin H, ACINUS, EfW1, PHAPII, LC-MS-MS, method, Homo sapiens, dmTAF1, Ms1, Taf230, ECTOL1, Injection, method used in an experiment, 4beta, Studies, L-Methionine, Del(8)44H, 6aalpha))-, Separated, INTERFASCICULAR FIBERLESS 1, Pedameth, TAF250, Search Engines, Taf200, Coenzyme R, MS1, MS2, iones, Etioniamid, ipp2a2, Acetylations, Taf1p, IFL1, OCTD, 10^[-6], taf-ibeta, (+)-cis-Hexahydro-2-oxo-1H-thieno[3, stem node, male sterility 1, Long-Term Effect, TAF, Controlled, Controlling, DYRK1, TAF[[II]]250, DL-Methionine, protein complex, igaad, l(3)84Ab, Biotin Gelfert, 5-(2-oxohexahydro-1H-thieno[3, 4]imidazole-4-valeric acid, Peptide, group, 2-ethyl-4-thiopyridylamide, LC/MS/MS, cis-Tetrahydro-2-oxothieno(3, 4]imidazoline-4-valeric acid, biotin, WI-38, p230, Protein, I2PP2A, TFIID, Dyrk1, (3alpha, tandem MS, Zystein, WMS2, Data Base, Biodermatin, DDA, Biotin-Ratiopharm, Separation, TAF[[II]]230, PRSS, nodal stem, MALE STERILITY 1 PROTEIN, 2-amino-3-sulfanylpropanoic acid, CC1, hexahydro-2-oxo-, Tripcellim, L-2-Amino-3-mercaptopropionic acid, TAF[II]250, Protein Gene Products, Trypure, dSET/TAF-Ibeta, 2610030F17Rik, DmelCG17603, Ion, Modern Man, SSKS, alpha-amino-gamma-methylmercaptobutyric acid, Peptid, assay, variable, SCH, AA407739, 6-diaminohexanoic acid, TAF1, 3-OHECNfalseLFQ_TurboID-PSMA6_ETP_Tamavidin2-REVThe control and ETP-treated WI-38 cells stably expressing α1-TurboID were seeded and cultured overnight. The cells were treated with 500 μM biotin for 1 h. Preparation of cell lysates, tryptic digestion, and enrichment of biotinylated peptides using Tamavidin 2-REV were performed as described previously (PMID: 32554809). LC-MS/MS analysis of the resultant peptides was performed on an EASY-nLC 1200 UHPLC connected to a Q Exactive mass spectrometer through a nanoelectrospray ion source (Thermo Fisher Scientific). The peptides were separated on a 75-μm-inner-diameter, 150-mm C18 reversed-phase column (Nikkyo Technos, Tokyo, Japan) with a linear 4–32% ACN gradient for 0–60 min, followed by an increase to 80% ACN for 10 min. The mass spectrometer was operated in data-dependent acquisition mode with a top 10 MS/MS method. MS1 spectra were measured with a resolution of 70,000, an AGC target of 1 × 106, and a mass range from 350 to 1,500 m/z. MS/MS spectra were triggered at a resolution of 17,500, an AGC target of 5 × 104, an isolation window of 2.0 m/z, a maximum injection time of 200 ms, and a normalized collision energy of 27. Dynamic exclusion was set to 15 s. Raw data were directly analyzed against the SwissProt database restricted to Homo sapiens using Proteome Discoverer (v.2.4; Thermo Fisher Scientific) with Sequest HT search engine. The search parameters were the following: (a) trypsin as an enzyme with up to two missed cleavages; (b) precursor mass tolerance of 10 ppm; (c) fragment mass tolerance of 0.02 Da; (d) carbamidomethylation of cysteine as a fixed modification; and (e) acetylation of protein N-terminus, oxidation of methionine, and biotinylation of lysine as variable modifications. Peptides were filtered at a false discovery rate <0.01 using the Percolator node in Proteome Discoverer. Label-free quantification was performed using the Precursor Ions Quantifier node.Fri Oct 21 00:00:00 BST 2022PXD0292729606